Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1219 ARTÍCULOS , VIENDO DEL 856 AL 870

Alzheimer's Disease and the Routine Clinical Use of CSF Biomarkers

Martorana A.

CNS Neurol Disord Drug Targets. 2017;16(4):407-413. doi: 10.2174/1871527316666170124164854.

Potential oxidative stress biomarkers of mild cognitive impairment due to Alzheimer disease

García-Blanco A, Baquero M, Vento M, Gil E, Bataller L, Cháfer-Pericás C.

J Neurol Sci. 2017 Feb 15;373:295-302. doi: 10.1016/j.jns.2017.01.020. Epub 2017 Jan 7.

Biomarkers for Alzheimer's Disease Diagnosis

Mantzavinos V, Alexiou A.

Curr Alzheimer Res. 2017;14(11):1149-1154. doi: 10.2174/1567205014666170203125942.

YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer's Disease

Muszyński P, Groblewska M, Kulczyńska-Przybik A, Kułakowska A, Mroczko B.

Curr Neuropharmacol. 2017;15(6):906-917. doi: 10.2174/1570159X15666170208124324.

Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept

Epelbaum S, Genthon R, Cavedo E, Habert MO, Lamari F, Gagliardi G, Lista S, Teichmann M, Bakardjian H, Hampel H, Dubois B.

Alzheimers Dement. 2017 Apr;13(4):454-467. doi: 10.1016/j.jalz.2016.12.003. Epub 2017 Feb 7.

Metabolomics in Alzheimer's disease: The need of complementary analytical platforms for the identification of biomarkers to unravel the underlying pathology

González-Domínguez R, Sayago A, Fernández-Recamales Á.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Dec 15;1071:75-92. doi: 10.1016/j.jchromb.2017.02.008. Epub 2017 Feb 6.

Diagnostic Validity Comparison Between Criteria Based on CSF Alzheimer's Disease Biomarkers

Blanco-Cantó ME, Monge-Argilés JA, Pérez-Cejuela C, Badía C, Gabaldón L, Muñoz-Ruíz C, Sánchez-Payá J, Gasparini-Berenguer R, Leiva-Santana C.

Am J Alzheimers Dis Other Demen. 2017 Mar;32(2):101-107. doi: 10.1177/1533317516688298.

Selenium Levels in Serum, Red Blood Cells, and Cerebrospinal Fluid of Alzheimer's Disease Patients: A Report from the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL)

Cardoso BR, Hare DJ, Bush AI, Li QX, Fowler CJ, Masters CL, Martins RN, Ganio K, Lothian A, Mukherjee S, Kapp EA, Roberts BR; AIBL research group.

J Alzheimers Dis. 2017;57(1):183-193. doi: 10.3233/JAD-160622.

Effect of a Comprehensive Intervention on Plasma BDNF in Patients with Alzheimer's Disease

Balietti M, Giuli C, Fattoretti P, Fabbietti P, Papa R, Postacchini D, Conti F.

J Alzheimers Dis. 2017;57(1):37-43. doi: 10.3233/JAD-161168.

A second wind for the cholinergic system in Alzheimer's therapy

Douchamps V, Mathis C.

Behav Pharmacol. 2017 Apr;28(2 and 3-Spec Issue):112-123. doi: 10.1097/FBP.0000000000000300.

Dysregulation of lipids in Alzheimer's disease and their role as potential biomarkers

Wong MW, Braidy N, Poljak A, Pickford R, Thambisetty M, Sachdev PS.

Alzheimers Dement. 2017 Jul;13(7):810-827. doi: 10.1016/j.jalz.2017.01.008. Epub 2017 Feb 24.

Molecular Links and Biomarkers of Stroke, Vascular Dementia, and Alzheimer's Disease

Vijayan M, Kumar S, Bhatti JS, Reddy PH.

Prog Mol Biol Transl Sci. 2017;146:95-126. doi: 10.1016/bs.pmbts.2016.12.014. Epub 2017 Feb 1.

Emerging biomarkers and screening for cognitive frailty

Ruan Q, D'Onofrio G, Sancarlo D, Greco A, Lozupone M, Seripa D, Panza F, Yu Z.

Aging Clin Exp Res. 2017 Dec;29(6):1075-1086. doi: 10.1007/s40520-017-0741-8. Epub 2017 Mar 4.

Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease

Baldacci F, Toschi N, Lista S, Zetterberg H, Blennow K, Kilimann I, Teipel S, Cavedo E, Dos Santos AM, Epelbaum S, Lamari F, Dubois B, Floris R, Garaci F, Bonuccelli U, Hampel H.

Alzheimers Dement. 2017 Sep;13(9):993-1003. doi: 10.1016/j.jalz.2017.01.021. Epub 2017 Mar 3.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias